Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Actelion launches drug in Japan for Niemann-Pick type C disease

May 31, 2012

Omni Bio provides updated results from pilot study in type 1 diabetes

May 31, 2012

FDA requires integrated safety analysis before continued studies of oral Proellex

May 31, 2012

Preliminary phase III data show efficacy for CompleoTRT

May 31, 2012

FDA accepts filing of NDA for Kynamro

May 30, 2012

Andromeda peptide product receives FDA orphan drug status

May 30, 2012

European CHMP recommends approval of Jentadueto

May 29, 2012

Scientists at Nektar Therapeutics present new polymer-GLP-1 conjugates

May 25, 2012

Novel cytochrome P450 inhibitors patented by German university

May 25, 2012

EMA acceptance of Takeda's alogliptin MAA triggers milestone payment for Furiex

May 24, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...